Jonas Jost B, Spandau Ulrich H, Harder Bjoern, Sauder Gangolf
Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Graefes Arch Clin Exp Ophthalmol. 2007 May;245(5):749-50. doi: 10.1007/s00417-006-0332-4. Epub 2006 May 4.
To report on the use of intravitreal triamcinolone acetonide as treatment for nonarteritic anterior ischemic optic neuropathy (NAION).
The interventional clinical case series included three patients with acute NAION who received an intravitreal injection of about 20 mg triamcinolone acetonide.
At the end of follow-up at 3 months, 3.5 months and at 5 months after the injection, visual acuity had changed from 0.10 at baseline to 0.20 in the first patient, from 0.50 to 0.20 in the second patient, and from 0.16 to 0.20 in the third patient. One eye developed triamcinolone-induced ocular hypertension which was treated by topical antiglaucomatous medication.
The clinical courses of all three patients presented suggest that an intravitreal high-dosage injection of triamcinolone acetonide may not be markedly effective in increasing visual acuity after acute NAION.
报告玻璃体内注射曲安奈德治疗非动脉炎性前部缺血性视神经病变（NAION）的应用情况。
该介入性临床病例系列包括3例急性NAION患者，他们接受了约20mg曲安奈德的玻璃体内注射。
在注射后3个月、3.5个月和5个月的随访结束时，第一名患者的视力从基线时的0.10提高到了0.20，第二名患者从0.50降至0.20，第三名患者从0.16提高到0.20。一只眼睛出现了曲安奈德诱导的高眼压，通过局部抗青光眼药物进行了治疗。
所有3例患者的临床病程表明，玻璃体内高剂量注射曲安奈德对急性NAION后提高视力可能没有明显效果。
